A federal judge in Tennessee has declined to certify two classes in an antitrust case accusing a subsidiary of Pfizer Inc. of conspiring to keep cheaper generic versions of its Skelaxin muscle relaxant off the market. In Thursday’s 67-page decision, U.S. District Judge Curtis Collier in Chattanooga found the cases brought on behalf of end payers and indirect purchasers of the drug were inappropriate for class treatment.
Kaye Scholer represents Pfizer’s King Pharmaceuticals unit in the litigation and Munger, Tolles & Olson represents codefendant Mutual Pharmaceuticals.
